Arcus Biosciences (NYSE: RCUS) reported Q3 EPS of ($0.94), $0.19 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $32 million versus the consensus estimate of $27.57 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.